everolimus
Dosage Form: tablet
FULL PRESCRIBING INFORMATION
• Increased susceptibility to infection and the possible development of malignancies such as lymphoma and skin cancer may result from immunosuppression. [See Warnings and Precautions (5.2)]
• Only physicians experienced in immunosuppressive therapy and management of transplant patients should prescribe Zortress. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient. [See Warnings and Precautions (5.1)]
• Increased nephrotoxicity can occur with use of standard doses of cyclosporine in combination with everolimus. Therefore reduced doses of cyclosporine should be used in combination with everolimus in order to reduce renal dysfunction. It is important to monitor the cyclosporine and everolimus whole blood trough concentrations. [See Dosage and Administration (2.2 and 2.3) and Warnings and Precautions (5.8) and Clinical Pharmacology (12.5 and 12.6)]
• An increased risk of kidney arterial and venous thrombosis, resulting in graft loss, was reported, mostly within the first 30 days post-transplantation. [See Warnings and Precautions (5.5)]
Indications and Usage for Zortress
Prophylaxis of Organ Rejection in Renal Transplantation
Zortress is indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant. [See Clinical Studies (14.1)] Zortress is to be administered in combination with basiliximab induction and concurrently with reduced doses of cyclosporine and corticosteroids. Therapeutic drug monitoring of everolimus and cyclosporine is recommended for all patients receiving these products. [See Dosage and Administration (2.2 and 2.3)]
Limitations of Use
• In patients at high immunologic risk, the safety and efficacy of everolimus has not been established.
• Use of everolimus for the prophylaxis of organ rejection in transplanted organs other than kidney has not been established.
• Standard doses of cyclosporine should be avoided with everolimus in order to reduce the risk of nephrotoxicity. [See Warnings and Precautions (5), and Adverse Reactions (6.2)]
• The safety and efficacy of Zortress has not been established in pediatric patients (<18 years).
Zortress Dosage and Administration
Dosage in Adult Kidney Transplant Patients
An initial everolimus dose of 0.75 mg orally twice daily (1.5 mg/day) is recommended for adult kidney transplant patients in combination with reduced dose cyclosporine, administered as soon as possible after transplantation. [See Therapeutic Drug Monitoring (2.2 and 2.3), Clinical Studies (14.1)] Patients receiving everolimus may require dose adjustments based on everolimus blood concentrations achieved, tolerability, individual response, change in concomitant medications and the clinical situation. Dose adjustments can be made at 4-5 day intervals. [See Therapeutic Drug Monitoring (2.2)]
Oral prednisone should be initiated once oral medication is tolerated. Steroid doses may be further tapered on an individualized basis depending on the clinical status of patient and function of graft.
Therapeutic Drug Monitoring - Everolimus
Routine everolimus whole blood therapeutic drug concentration monitoring is recommended for all patients using appropriate assay methodology. The recommended everolimus therapeutic range is 3 to 8 ng/mL. [See Clinical Pharmacology (12.5)] Careful attention should be made to clinical signs and symptoms, tissue biopsies, and laboratory parameters.
It is important to monitor everolimus blood concentrations, in patients with hepatic impairment, during concomitant administration of CYP3A4 inducers or inhibitors, when switching cyclosporine formulations and/or when cyclosporine dosing is reduced according to recommended target concentrations. [See Clinical Pharmacology (12.5 and 12.6)]
Optimally, dose adjustments of everolimus should be based on trough concentrations obtained 4 or 5 days after a previous dosing change. There is an interaction of cyclosporine on everolimus, and consequently, everolimus concentrations may decrease if cyclosporine exposure is reduced. [See Drug Interactions (7.2)]
Therapeutic Drug Monitoring- Cyclosporine
Both cyclosporine doses and the target range for whole blood trough concentrations should be reduced, when given in a regimen with everolimus, in order to minimize the risk of nephrotoxicity. [See Warnings and Precautions (5.8) and Drug Interactions (7.2), Clinical Pharmacology (12.6)]
The recommended cyclosporine therapeutic range when administered with everolimus are 100 to 200 ng/mL through Month 1 post-transplant, 75 to 150 ng/mL at Months 2 and 3 post-transplant, 50 to 100 ng/mL at Month 4 post-transplant, and 25 to 50 ng/mL from Month 6 through Month 12 post-transplant. The median trough concentrations observed in the clinical trial ranged between 161 to 185 ng/mL through Month 1 post-transplant and between 111 to 140 ng/mL at Months 2 and 3 post-transplant. The median trough concentration was 99 ng/mL at Month 4 post-transplant and ranged between 46 to 75 ng/mL from Months 6 through Month 12 post-transplant. [See Clinical Pharmacology (12.6) and Clinical Studies (14.1)]
Cyclosporine, USP Modified is to be administered as oral capsules twice daily unless cyclosporine oral solution or i.v. administration of cyclosporine cannot be avoided. Cyclosporine, USP Modified should be initiated as soon as possible - and no later than 48 hours - after reperfusion of the graft and dose adjusted to target concentrations from Day 5 onwards.
If impairment of renal function is progressive the treatment regimen should be adjusted. In renal transplant patients, the cyclosporine dose should be based on cyclosporine whole blood trough concentrations. [See Clinical Pharmacology (12.6)]
In renal transplantation, there are limited data regarding dosing everolimus with reduced cyclosporine trough concentrations of 25 to 50 ng/mL after 12 months. Everolimus has not been evaluated in clinical trials with other formulations of cyclosporine. Prior to dose reduction of cyclosporine it should be ascertained that steady-state everolimus whole blood trough concentration is at least 3 ng/mL. There is an interaction of cyclosporine on everolimus, and consequently, everolimus concentrations may decrease if cyclosporine exposure is reduced. [See Drug Interactions (7.2)]
Administration
Everolimus tablets should be swallowed whole with a glass of water and not crushed before use.
Administer everolimus consistently approximately 12 hours apart with or without food to minimize variability in absorption and at the same time as cyclosporine. [See Clinical Pharmacology (12.3)]
Hepatic Impairment
No dose adjustment is needed for patients with mild hepatic impairment (Child-Pugh Class A). In patients with moderate hepatic impairment (Child-Pugh Class B), the daily dose needs to be reduced by one-half the recommended initial daily dose and blood concentrations should be monitored to make further adjustments as necessary. There is no information on the effects of severe hepatic impairment (Child-Pugh Class C) on everolimus pharmacokinetics. [See Clinical Pharmacology (12.3)]
Dosage Forms and Strengths
Zortress is available as 0.25 mg, 0.5 mg, and 0.75 mg tablets.
| Dosage Strength | 0.25 mg | 0.5 mg | 0.75 mg |
| Appearance | White to yellowish, marbled, round, flat tablets with bevelled edge | ||
| Imprint | “C” on one side and “NVR” on the other | “CH” on one side and “NVR” on the other | “CL” on one side and “NVR” on the other |
Contraindications
Hypersensitivity Reactions
Zortress is contraindicated in patients with known hypersensitivity to everolimus, sirolimus, or to components of the drug product.
Warnings and Precautions
Management of Immunosuppression
Only physicians experienced in management of systemic immunosuppressant therapy in transplantation should prescribe Zortress. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for the maintenance therapy should have complete information requisite for the follow-up of the patient. [See Boxed Warning]
Lymphomas and Other Malignancies
Patients receiving immunosuppressants, including everolimus, are at increased risk of developing lymphomas and other malignancies, particularly of the skin. [See Boxed Warning] The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent.
As usual for patients with increased risk for skin cancer, exposure to sunlight and ultraviolet light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.
Serious Infections
Patients receiving immunosuppressants, including everolimus, are at increased risk of developing bacterial, viral, fungal, and protozoal infections, including opportunistic infections. [See Warnings and Precautions (5.10) and Adverse Reactions (6.2)] These infections may lead to serious, including fatal, outcomes. Because of the danger of over immunosuppression of the immune system which can cause increased susceptibility to infection, combination immunosuppressant therapy should be used with caution.
Angioedema
Zortress has been associated with the development of angioedema. The concomitant use of everolimus with other drugs known to cause angioedema, such as angiotensin converting enzyme (ACE) inhibitors may increase the risk of developing angioedema.
Graft Thrombosis
An increased risk of kidney arterial and venous thrombosis, resulting in graft loss, has been reported, usually within the first 30 days post-transplantation. [See Boxed Warning]
Wound Healing and Fluid Accumulation
Everolimus delays wound healing and increases the occurrence of wound-related complications like wound dehiscence, wound infection, incisional hernia, lymphocele and seroma. These wound-related complications may require more surgical intervention. Generalized fluid accumulation, including peripheral edema (e.g., lymphoedema) and other types of localized fluid collection, such as pericardial and pleural effusions and ascites have also been reported.
Hyperlipidemia
Increased serum cholesterol and triglycerides, requiring the need for anti-lipid therapy, have been reported to occur following initiation of everolimus and the risk of hyperlipidemia is increased with higher everolimus whole blood trough concentrations. [See Adverse Reactions (6.2)] Use of anti-lipid therapy may not normalize lipid levels in patients receiving Zortress.
Any patient who is administered everolimus should be monitored for hyperlipidemia. If detected, interventions, such as diet, exercise, and lipid-lowering agents should be initiated as outlined by the National Cholesterol Education Program guidelines. The risk/benefit should be considered in patients with established hyperlipidemia before initiating an immunosuppressive regimen containing everolimus. Similarly, the risk/benefit of continued everolimus therapy should be re-evaluated in patients with severe refractory hyperlipidemia. Everolimus has not been studied in patients with baseline cholesterol levels >350 mg/dL.
Due to an interaction with cyclosporine, clinical trials of everolimus and cyclosporine in kidney transplant patients strongly discouraged patients from receiving the HMG-CoA reductase inhibitors simvastatin and lovastatin. During everolimus therapy with cyclosporine, patients administered an HMG-CoA reductase inhibitor and/or fibrate should be monitored for the possible development of rhabdomyolysis and other adverse effects, as described in the respective labeling for these agents. [See Drug Interactions (7.6)]
Nephrotoxicity
Everolimus with standard dose cyclosporine increases the risk of nephrotoxicity resulting in a lower glomerular filtration rate. Reduced doses of cyclosporine are required for use in combination with everolimus in order to reduce renal dysfunction. [See Boxed Warning, Indications and Usage (1.2), Clinical Pharmacology (12.6)] Renal function should be monitored during the administration of everolimus in combination with cyclosporine. Consider switching to other immunosuppressive therapies if renal function does not improve after dose adjustments or if the dysfunction is thought to be drug related. Caution should be exercised when using other drugs which are known to impair renal function.
Proteinuria
The use of everolimus with cyclosporine in transplant patients has been associated with increased proteinuria. The risk of proteinuria increased with higher everolimus whole blood trough concentrations. Patients receiving everolimus should be monitored for proteinuria. [See Adverse Reactions (6.2)]
Polyoma Virus Infections
Patients receiving immunosuppressants, including everolimus, are at increased risk for opportunistic infections; including polyoma virus infections. [See Boxed Warning] BK virus-associated nephropathy (BKVAN) has been observed in patients receiving everolimus. BKVAN is associated with serious outcomes; including deteriorating renal function and renal graft loss. [See Adverse Reactions (6.2)] Patient monitoring may help detect patients at risk for BK virus-associated nephropathy. Reductions in immunosuppression should be considered for patients who develop evidence of BK virus-associated nephropathy.
Interaction with Strong Inhibitors and Inducers of CYP3A4
Co-administration with strong CYP3A4-inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir) and strong inducers (e.g., rifampin, rifabutin) is not recommended without close monitoring of everolimus whole blood trough concentrations. [See Drug Interactions (7)]
Non-Infectious Pneumonitis
A diagnosis of non-infectious pneumonitis should be considered in patients presenting with symptoms consistent with infectious pneumonia or radiologic changes in whom infectious, neoplastic and other non-drug causes have been ruled out through appropriate investigations. Fatal cases have been reported. Non-infectious pneumonitis may respond to drug interruption with or without glucocorticoid therapy. [See Adverse Reactions (6.2)]
Thrombotic Microangiopathy/ Thrombotic Thrombocytopenic Purpura/ Hemolytic Uremic Syndrome (TMA/TTP/HUS)
The concomitant use of everolimus with cyclosporine may increase the risk of thrombotic microangiopathy/thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Monitor hematologic parameters. [See Adverse Reactions (6.2)]
New Onset Diabetes After Transplant
Everolimus has been shown to increase the risk of new onset diabetes mellitus after transplant. Blood glucose concentrations should be monitored closely in patients using everolimus.
Male Infertility
Azospermia or oligospermia may be observed. [See Adverse Reactions (6.3) and Carcinogenesis, Mutagenesis, Impairment of Fertility (13.1)] Everolimus is an anti-proliferative drug and affects rapidly dividing cells like the germ cells.
Immunizations
The use of live vaccines should be avoided during treatment with everolimus; examples include (not limited to) the following: intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines.
Interaction with Grapefruit Juice
Grapefruit and grapefruit juice inhibit cytochrome P450 3A4 and P-gp activity and should therefore be avoided with concomitant use of everolimus and cyclosporine.
Patients with Hereditary Disorders / Other
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take everolimus as this may result in diarrhea and malabsorption.
Adverse Reactions
Serious and Otherwise Important Adverse Reactions
The following adverse reactions are discussed in greater detail in other sections of the label.
- Hypersensitivity reactions [See Contraindications (4.1)]
- Lymphomas and Other Malignancies [See Boxed Warning, Warnings and Precautions (5.2)]
- Serious Infections [See Warnings and Precautions (5.3)]
- Angioedema [See Warnings and Precautions (5.4)]
- Graft Thrombosis [See Warnings and Precautions (5.5)]
- Wound Healing and Fluid Accumulation [See Warnings and Precautions (5.6)]
- Hyperlipidemia [See Warnings and Precautions (5.7)]
- Nephrotoxicity [See Warnings and Precautions (5.8)]
- Proteinuria [See Warnings and Precautions (5.9)]
- Polyoma Virus Infections [See Warnings and Precautions (5.10)]
- Non-infectious Pneumonitis [See Warnings and Precautions (5.12)]
- Thrombotic Microangiopathy/Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TMA/TTP/HUS) [See Warnings and Precautions (5.13)]
- New Onset Diabetes After Transplant [See Warnings and Precautions (5.14)]
- Male Infertility [See Warnings and Precautions (5.15)]
Clinical Studies Experience
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other trials and may not reflect the rates observed in clinical practice.
The data described below reflect exposure to everolimus in an open-label, randomized trial of de novo kidney transplant patients of concentration-controlled everolimus at an initial starting dose of 1.5 mg per day [target trough concentrations 3 to 8 ng/mL with reduced doses of cyclosporine (n=274) compared to mycophenolic acid (n=273) with standard doses of cyclosporine]. All patients received basiliximab induction therapy and corticosteroids. The population was between 18 and 70 years; more than 43% were 50 years of age or older, 63% of all recipients were male and 64% were Caucasian. Demographic characteristics were comparable between treatment groups. The most frequent diseases leading to transplantation were balanced between groups and included hypertension/nephrosclerosis, glomerulonephritis/glomerular disease and diabetes mellitus.
Adverse reactions were systematically collected in this trial.
In this clinical trial, significantly more patients discontinued everolimus 1.5 mg/day treatment (83/277, 30%) than discontinued the control regimen (60/277, 22%). Of those patients who prematurely discontinued treatment, most discontinuations were due to adverse reactions: 18% in the everolimus group compared to 9% in the control group (p-value = 0.004). This difference was more prominent between treatment groups among female patients. In those patients discontinuing study medication, adverse reactions were collected up to 7 days after study medication discontinuation and serious adverse reactions up to 30 days after study medication discontinuation.
Discontinuation of everolimus at a higher dose (3 mg/day) was 95/279, 34%, including 20% due to adverse reactions, and this regimen is not recommended (see below).
The overall incidences of serious adverse events were 57% (159/278) in the everolimus group and 52% (141/273) in the mycophenolic acid group. Infections and infestations reported as serious adverse reactions had the highest incidence in both groups [20% (54/274) in the everolimus group and 25% (69/273) in the control group]. The difference was mainly due to the higher incidence of viral infections in the Myfortic group, mainly CMV and BK virus infections. Injury, poisoning and procedural complications reported as serious adverse reactions had the second highest incidence in both groups [14% (39/274) in the everolimus group and 12% (32/273) in the control group] followed by renal and urinary disorders [10% (28/274) in the everolimus group and 13% (36/273) in the control group] and vascular disorders [10% (26/274) in the everolimus group and 7% (20/273) in the control group].
A total of 13 patients died during the first 12 months of study; 7 (3%) in the everolimus group and 6 (2%) in the control group. The most common causes of death across the study groups were related to cardiac conditions and infections.
There were 12 (4%) graft losses in the everolimus group and 8 (3%) in the control group over the 12 month study period. Of the graft losses, 4 were due to renal artery and two due to renal vein thrombosis in the everolimus group (2%) compared to two renal artery thromboses in the control group (1%). [See Boxed Warning and Warnings and Precautions (5.5)]
The most common (≥20%) adverse reactions observed in the everolimus group were: peripheral edema, constipation, hypertension, nausea, anemia, urinary tract infection, and hyperlipidemia.
Infections
The overall incidence of bacterial, fungal and viral infections reported as adverse reactions was higher in the control group (68%) compared to the everolimus group (64%) and was primarily due to an increased number of viral infections (21% in the control group and 10% in the everolimus group). The incidence of cytomegalovirus (CMV) infections reported as adverse reactions was 8% in the control group compared to 1% in the everolimus group; and 3% of the serious CMV infections in the control group versus 0% in the everolimus group were considered serious. [See Warnings and Precautions (5.3)]
BK Virus
BK virus infections were lower in incidence in the everolimus group (2 patients, 1%) compared to the control group (11 patients, 4%). One of the two BK virus infections in the everolimus group and two of the 11 BK virus infections in the control group were also reported as serious adverse events. BK virus infections did not result in graft loss in any of the groups in the clinical trial.
Wound Healing and Fluid Collections
Wound healing-related reactions were identified through a retrospective search and request for additional data. The overall incidence of wound-related events, including lymphocele, seroma, hematoma, dehiscence, incisional hernia, and infections was 35% in the everolimus group compared to 26% in the control group. More patients required intraoperative repair debridement or drainage of incisional wound complications and more required drainage of lymphoceles and seromas in the everolimus group compared to control.
Adverse reactions due to major fluid collections such as edema and other types of fluid collections was 45% in the everolimus group and 40% in the control group. [See Warnings and Precautions (5.6)]
Neoplasms
Adverse events due to malignant and benign neoplasms were reported in 3% of patients in the everolimus group and 6% in the control group. The most frequently reported neoplasms in the control group were basal cell carcinoma, squamous cell carcinoma, skin papilloma and seborrhoeic keratosis. One patient in the everolimus group who underwent a melanoma excision prior to transplantation died due to metastatic melanoma. [See Boxed Warning and Warnings and Precautions (5.2)]
New Onset Diabetes Mellitus (NODM)
NODM reported based on adverse reactions and random serum glucose values, was 9% in the everolimus group compared to 7% in the control group.
Endocrine Effects in Males
In the everolimus group, serum testosterone levels significantly decreased while the FSH levels significantly increased without significant changes being observed in the control group. In both the everolimus and the control groups mean testosterone and FSH levels remained within the normal range with the mean FSH level in the everolimus group being at the upper limit of the normal range (11.1 U/L). More patients were reported with erectile dysfunction in the everolimus treatment group compared to the control group (5% compared to 2%, respectively).
Table 1 compares the incidence of treatment-emergent adverse reactions reported with an incidence of ≥10% for patients receiving everolimus with reduced dose cyclosporine or mycophenolic acid with standard dose cyclosporine. Within each MedDRA system organ class, the adverse reactions are presented in order of decreasing frequency.
| Primary System Organ Class Preferred Term | Zortress (everolimus) 1.5 mg With reduced dose cyclosporine N=274 / n (%) | Myfortic (mycophenolic acid) 1.44 g With standard dose cyclosporine N=273 / n (%) |
| Any Adverse Events* | 271 (99) | 270 (99) |
| Blood lymphatic system disorders | 93 (34) | 111 (41) |
| Anemia | 70 (26) | 68 (25) |
| Leukopenia | 8 (3) | 33 (12) |
| Gastrointestinal disorders | 196 (72) | 207 (76) |
| Constipation | 105 (38) | 117 (43) |
| Nausea | 79 (29) | 85 (31) |
| Diarrhea | 51 (19) | 54 (20) |
| Vomiting | 40 (15) | 60 (22) |
| Abdominal pain | 36 (13) | 42 (15) |
| Dyspepsia | 12 (4) | 31 (11) |
| Abdominal pain upper | 9 (3) | 30 (11) |
| General disorders and administrative site conditions | 181 (66) | 160 (59) |
| Edema peripheral | 123 (45) | 108 (40) |
| Pyrexia | 51 (19) | 40 (15) |
| Fatigue | 25 (9) | 28 (10) |
| Infections and infestations | 169 (62) | 185 (68) |
| Urinary tract infection | 60 (22) | 63 (23) |
| Upper respiratory tract infection | 44 (16) | 49 (18) |
| Injury, poisoning and procedural complications | 163 (60) | 163 (60) |
| Incision site pain | 45 (16) | 47 (17) |
| Procedural pain | 40 (15) | 37 (14) |
| Investigations | 137 (50) | 133 (49) |
| Blood creatinine increased | 48 (18) | 59 (22) |
| Metabolism and nutrition disorders | 222 (81) | 199 (73) |
| Hyperlipidemia | 57 (21) | 43 (16) |
| Hyperkalemia | 49 (18) | 48 (18) |
| Hypercholesterolemia | 47 (17) | 34 (13) |
| Dyslipidemia | 41 (15) | 24 (9) |
| Hypomagnesemia | 37 (14) | 40 (15) |
| Hypophosphatemia | 35 (13) | 35 (13) |
| Hyperglycemia | 34 (12) | 38 (14) |
| Hypokalemia | 32 (12) | 32 (12) |
| Musculoskeletal and connective tissue disorders | 112 (41) | 105 (39) |
| Pain in extremity | 32 (12) | 29 (11) |
| Back pain | 30 (11) | 28 (10) |
| Nervous system disorders | 92 (34) | 109 (40) |
| Headache | 49 (18) | 40 (15) |
| Tremor | 23 (8) | 38 (14) |
| Psychiatric disorders | 90 (33) | 72 (26) |
| Insomnia | 47 (17) | 43 (16) |
| Renal and urinary disorders | 112 (41) | 124 (45) |
| Hematuria | 33 (12) | 33 (12) |
| Dysuria | 29 (11) | 28 (10) |
| Respiratory, thoracic and mediastinal disorders | 86 (31) | 93 (34) |
| Cough | 20 (7) | 30 (11) |
| Vascular disorders | 122 (45) | 124 (45) |
| Hypertension | 81 (30) | 82 (30) |
* As reported in the safety analysis population defined as all randomized patients who received at least one dose of treatment and had at least one post-baseline safety assessment.
Adverse events that occurred with at least a 5% higher frequency in the everolimus 1.5 mg group compared to the control group were: peripheral edema (45% compared to 40%), hyperlipidemia (21% compared to 16%), dyslipidemia (15% compared to 9%), and stomatitis/mouth ulceration (8% compared to 3%).
A third treatment group of everolimus 3.0 mg per day (1.5 mg twice daily; target trough concentrations 6 to 12 ng/mL) with reduced-dose cyclosporine was included in the study described above. Although as effective as the lower dose everolimus group, the overall safety was worse and consequently higher doses of everolimus cannot be recommended. Out of 279 patients, 95 (34%) discontinued the study medication with 57 (20%) doing so because of adverse reactions. The most frequent adverse reactions leading to discontinuation of everolimus when used at this higher dose were injury, poisoning and procedural complications (everolimus 1.5 mg: 5%, everolimus 3.0 mg: 7%, and control: 2%), infections (2%, 6%, and 3%, respectively), renal and urinary disorders (4%, 7%, and 4%, respectively) and gastrointestinal disorders (1%, 3%, and 2%).
Less common adverse reactions, occurring in ≥1% to <10% of patients treated with everolimus include:
Blood and Lymphatic System Disorders: leukocytosis, leucopenia, lymphadenopathy, thrombocythemia, thrombocytopenia
Cardiac and Vascular Disorders: angina pectoris, atrial fibrillation, cardiac failure congestive, palpitations, tachycardia, hypertension including hypertensive crisis, hypotension, deep vein thrombosis
Endocrine Disorders: Cushingoid, hyperparathyroidism
Eye Disorders: cataract, conjunctivitis, vision blurred
Gastrointestinal Disorders: abdominal pain, abdominal distention, dyspepsia, dysphagia, epigastric discomfort, flatulence, gastroesophageal reflux disease, gingival hypertrophy, hematemesis, hemorrhoids, ileus, mouth ulceration, peritonitis, stomatitis
General Disorders and Administrative Site Conditions: chest discomfort, chest pain, chills, fatigue, malaise, edema including generalized edema
Hepatobiliary Disorders: hepatic enzyme increased, bilirubin increased
Infections and Infestations: BK virus infection [See Warnings and Precautions (5.10)], bacteremia, bronchitis, candidiasis, cellulitis, folliculitis, gastroenteritis, influenza, nasopharyngitis, onychomycosis, oral candidiasis, osteomyelitis, pneumonia, pyelonephritis, sinusitis, tinea pedis, urethritis, wound infection, herpes infections [See Boxed Warning and Warnings and Precautions (5.2)]
Injury Poisoning and Procedural Complications: incision site complications including infections, perinephric collection, seroma, wound dehiscence, incisional hernia, perinephric hematoma, localized intraabdominal fluid collection, impaired healing, lymophocele, lymphorrhea
Metabolism and Nutrition Disorders: blood urea increased, acidosis, anorexia, dehydration, diabetes mellitus [See Warnings and Precautions (5.14)], fluid retention, gout, hypercalcemia, hypercholesterolemia [See Warnings and Precautions (5.7)], hyperphosphatemia, hypertriglyceridemia, hyperuricemia, hypocalcemia, hypoglycemia, hyponatremia, iron deficiency, vitamin B12 deficiency
Musculoskeletal and Connective Tissues Disorders: arthralgia, joint swelling, muscle spasms, muscular weakness, musculoskeletal pain, myalgia, osteonecrosis, osteopenia, osteoporosis, spondylitis
Nervous System Disorders: dizziness, hemiparesis, hypoaesthesia, paresthesia, somnolence, syncope, tremor
Psychiatric Disorders: agitation, anxiety, depression, hallucination
Renal and Urinary Disorders: bladder spasm, hydronephrosis, micturation urgency, nephritis interstitial, pollakiuria, polyuria, proteinuria [See Warnings and Precautions (5.9)], pyuria, renal artery thrombosis [See Boxed Warning and Warnings and Precautions (5.5)], acute renal failure, renal impairment [See Warnings and Precautions (5.8)], urinary retention
Reproductive System and Breast Disorders: erectile dysfunction, ovarian cyst, scrotal edema
Respiratory, Thoracic, Mediastinal Disorders: atelectasis, cough, dyspnea, epistaxis, nasal congestion, pleural effusions, pulmonary edema, rhinorrhea, sinus congestion, wheezing
Skin and Subcutaneous Tissue Disorders: alopecia, dermatitis acneiform, hirsutism, hyperhydrosis, hypertrichosis, night sweats, pruritus, rash
Less common, serious adverse reactions include:
•Non-infectious Pneumonitis [See Warnings and Precautions (5.12) and Adverse Reactions (6.2)]
•Thrombotic Microangiopathy (TMA), Thrombotic Thrombocytopenic Purpura (TTP), and Hemolytic Uremic Syndrome (HUS) [See Warnings and Precautions (5.13)]
The combination of fixed dose everolimus and standard doses cyclosporine in previous clinical trials resulted in frequent elevations of serum creatinine with higher mean and median serum creatinine values was observed than in the current study with reduced doses of cyclosporine. These results indicate that everolimus increases the cyclosporine-induced nephrotoxicity; and therefore should only be used in a concentration-controlled regimen with reduced doses of cyclosporine. [See Boxed Warnings, Indications and Usage (1.2) and Warnings and Precautions (5.8)]
Post Marketing Experience
Adverse reactions identified from the post-marketing use of the combination regimen of everolimus and cyclosporine that are not specific to any one transplant indication include angioedema [See Warnings and Precautions (5.4)] and pancreatitis. There have also been reports of male infertility with mTOR inhibitors including everolimus. [See Warnings and Precautions (5.15)].
Drug Interactions
Interactions with Strong Inhibitors or Inducers of CYP3A4 and P-glycoprotein
Everolimus is mainly metabolized by CYP3A4 in the liver and to some extent in the intestinal wall and is a substrate for the multidrug efflux pump, P-glycoprotein. Therefore, absorption and subsequent elimination of systemically absorbed everolimus may be influenced by medicinal products that affect CYP3A4 and/or P-glycoprotein. Concurrent treatment with strong inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir) and inducers (e.g., rifampin, rifabutin) of CYP3A4 is not recommended. Inhibitors of P-glycoprotein (e.g., digoxin, cyclosporine) may decrease the efflux of everolimus from intestinal cells and increase everolimus blood concentrations. In vitro, everolimus was a competitive inhibitor of CYP3A4 and of CYP2D6, potentially increasing the concentrations of medicinal products eliminated by these enzymes. Thus, caution should be exercised when co-administering everolimus with CYP3A4 and CYP2D6 substrates with a narrow therapeutic index. [See Therapeutic Drug Monitoring (2.2)]
All in vivo interaction studies were conducted without concomitant cyclosporine. Pharmacokinetic interactions between everolimus and concomitantly administered drugs are discussed below. Drug interaction studies have not been conducted with drugs other than those described below.
Cyclosporine (CYP3A4/P-gp inhibitor and CYP3A4 substrate)
The steady-state Cmax and AUC estimates of everolimus were significantly increased by co-administration of single dose cyclosporine. [See Clinical Pharmacology (12.3)] Dose adjustment of everolimus might be needed if the cyclosporine dose is altered. [See Dosage and Administration (2.3)] Everolimus had a clinically minor influence on cyclosporine pharmacokinetics in transplant patients receiving cyclosporine (Neoral).
Ketoconazole (Strong CYP3A4 Inhibitor)
Multiple-dose ketoconazole administration to healthy volunteers significantly increased single dose estimates of everolimus Cmax, AUC, and half-life. It is recommended that strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir) not be co-administered with everolimus. [See Warnings and Precautions (5.11), and Clinical Pharmacology (12.3)]
Erythromycin (Moderate CYP3A4 Inhibitor)
Multiple-dose erythromycin administration to healthy volunteers significantly increased single dose estimates of everolimus Cmax, AUC, and half-life. If erythromycin is co-administered, everolimus blood concentrations should be monitored and a dose adjustment made as necessary. [See Clinical Pharmacology (12.3)]
Verapamil (CYP3A4 and P-gp Substrate)
Multiple-dose verapamil administration to healthy volunteers significantly increased single dose estimates of everolimus Cmax and AUC. Everolimus half-life was not changed. If verapamil is co-administered, everolimus blood concentrations should be monitored and a dose adjustment made as necessary. [See Clinical Pharmacology (12.3)]
Atorvastatin (CYP3A4 substrate) and Pravastatin (P-gp substrate)
Single-dose administration of everolimus with either atorvastatin or pravastatin to healthy subjects did not influence the pharmacokinetics of atorvastatin, pravastatin and everolimus, as well as total HMG-CoA reductase bioreactivity in plasma to a clinically relevant extent. However, these results cannot be extrapolated to other HMG-CoA reductase inhibitors. Patients should be monitored for the development of rhabdomyolysis and other adverse events as described in the respective labeling for these products.
Simvastatin and Lovastatin
Due to an interaction with cyclosporine, clinical studies of everolimus with cyclosporine conducted in kidney transplant patients strongly discouraged patients with receiving HMG-CoA reductase inhibitors such as simvastatin and lovastatin. [See Warnings and Precautions (5.7)]
Rifampin (Strong CYP3A4) Inducers
Pre-treatment of healthy subjects with multiple-dose rifampin followed by a single dose of everolimus increased everolimus clearance and decreased the everolimus Cmax and AUC estimates. Combination with rifampin is not recommended. [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)]
Other Possible Interactions
Moderate inhibitors of CYP3A4 and P-gp may increase everolimus blood concentrations (e.g., fluconazole; macrolide antibiotics; nicardipine, diltiazem; nelfinavir, indinavir, amprenavir). Inducers of CYP3A4 may increase the metabolism of everolimus and decrease everolimus blood concentrations (e.g., St. John’s Wort [Hypericum perforatum]; anticonvulsants: carbamazepine, phenobarbital, phenytoin; efavirenz, nevirapine).
USE IN SPECIFIC POPULATIONS
Pregnancy
Pregnancy Category C
There are no adequate and well-controlled studies of everolimus in pregnant women. In rats and rabbits, everolimus crossed the placenta and was toxic to the conceptus. The potential risk for humans is unknown. Everolimus should be given to pregnant women only if the potential benefit to the mother justifies the potential risk to the fetus. Women of childbearing potential should be advised to use effective contraception methods while they are receiving everolimus and up to 8 weeks after treatment has been stopped.
Everolimus administered daily to pregnant rats by oral gavage at 0.1 mg/kg from before mating through organogenesis resulted in increased preimplantation loss and early resorptions of fetal implants. AUCs in rats at this dose were approximately one-third those in humans administered the starting dose (0.75 mg twice daily). Everolimus administered daily by oral gavage at 0.8 mg/kg to pregnant rabbits during organogenesis resulted in increased late resorptions of fetal implants. At this dose, AUCs in rabbits were slightly less than the AUCs in humans administered the starting clinical dose.
Nursing Mothers
It is not known whether everolimus is excreted in human milk. Everolimus and/or its metabolites readily transferred into milk of lactating rats at a concentration 3.5 times higher than in maternal serum. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from everolimus, women should avoid breast-feeding during treatment with Zortress.
Pediatric Use
The safe and effective use of Zortress in kidney transplant patients younger than 18 years of age has not been established. [See Clinical Pharmacology (12.4)]
Geriatric Use
There is limited clinical experience on the use of Zortress in patients of age 65 or older. There is no evidence to suggest that elderly patients will require a different dosage recommendation from younger adult patients. [See Clinical Pharmacology (12.4)]
Hepatic Impairment
No dosage adjustment is needed for patients with mild hepatic impairment (Child-Pugh Class A). In patients with moderate hepatic impairment (Child-Pugh Class B), the daily dose needs to be reduced by one-half recommended initial daily dose. There is no information on the effects of severe hepatic impairment (Child-Pugh Class C) on everolimus pharmacokinetics. [See Clinical Pharmacology (12.3)]
Renal Impairment
No dose adjustment is needed in patients with renal impairment. [See Clinical Pharmacology (12.3)]
Overdosage
Reported experience with overdose in humans is very limited. There is a single case of an accidental ingestion of 1.5 mg everolimus in a two-year-old child where no adverse reactions were observed. Single doses up to 25 mg have been administered to transplant patients with acceptable acute tolerability. Single doses up to 70 mg (without cyclosporine) have been given with acceptable acute tolerability. General supportive measures should be followed in all cases of overdose. Everolimus is not considered dialyzable to any relevant degree (<10% of everolimus removed within 6 hours of hemodialysis). In animal studies, everolimus showed a low acute toxic potential. No lethality or severe toxicity was observed after single oral doses of 2000 mg/kg (limit test) in either mice or rats.
Zortress Description
Zortress (everolimus) is a macrolide immunosuppressant.
The chemical name of everolimus is
(1R, 9S, 12S, 15R, 16E, 18R, 19R, 21R, 23S, 24E, 26E, 28E, 30S, 32S, 35R)-1, 18 - dihydroxy - 12 - {(1R) - 2 - [(1S,3R,4R) - 4 - (2 - hydroxyethoxy) - 3 - methoxycyclohexyl] - 1 - methylethyl} - 19,30 - dimethoxy - 15, 17, 21, 23, 29, 35-hexamethyl-11, 36-dioxa-4-aza-tricyclo[30.3.1.04,9] hexatriaconta-16,24,26,28-tetraene-2, 3,10,14,20-pentaone.
The molecular formula is C53H83NO14 and the molecular weight is 958.25. The structural formula is
Everolimus is supplied as tablets for oral administration containing 0.25 mg, 0.5 mg and 0.75 mg of everolimus together with butylated hydroxytoluene, magnesium stearate, lactose monohydrate, hypromellose, crospovidone and lactose anhydrous as inactive ingredients.
CLINICAL PHARMACOLOGY
Mechanism of Action
Everolimus inhibits antigenic and interleukin (IL-2 and IL-15) stimulated activation and proliferation of T and B lymphocytes.
In cells, everolimus binds to a cytoplasmic protein, the FK506 Binding Protein-12 (FKBP-12), to form an immunosuppressive complex (everolimus: FKBP-12) that binds to and inhibits the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. In the presence of everolimus phosphorylation of p70 S6 ribosomal protein kinase (p70S6K), a substrate of mTOR, is inhibited. Conseq
No comments:
Post a Comment